• Stoke Therapeutics recently completed enrollment of 162 patients in its global Phase 3 EMPEROR study of zorevunersen for Dravet syndrome, and outlined plans to begin a rolling New Drug Application submission to the US FDA in early 2027 with full Phase 3 data expected later that year.
• This milestone underscores how far Stoke’s lead program has progressed, with no treatment discontinuations reported to date and global expansion underway in Europe and China alongside its collaboration with Biogen.
• Next, we’ll examine how completing Phase 3 enrollment for zorevunersen and outlining the 2027 regulatory timeline could reshape Stoke’s investment narrative.

We've uncovered the 9 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

Stoke Therapeutics Investment Narrative Recap

To own Stoke Therapeutics, you need to believe zorevunersen can clear late stage trials and secure approval in Dravet syndrome. The completed EMPEROR Phase 3 enrollment and clarified 2027 rolling NDA timeline reinforce the importance of this program as the key near term catalyst, while clinical and regulatory outcomes for zorevunersen remain the central risk. The new data on trial progress does not yet change that risk reward balance in a material way.

The most relevant recent development around this catalyst is Stoke’s removal from several Russell indexes, which can affect trading liquidity and passive ownership but does not alter the clinical or regulatory path for EMPEROR. Taken together with the global expansion of the zorevunersen program, these updates highlight a company whose share price may move on both trial milestones and technical market factors that sit outside the science.

Yet against this clinical momentum, investors should still pay close attention to the risk that long term safety findings could...

Stoke Therapeutics' narrative projects $177.8 million revenue and $33.6 million earnings by 2029. This requires 77.0% yearly revenue growth and a $203.4 million earnings increase from -$169.8 million today.

Uncover how Stoke Therapeutics' forecasts yield a $45.10 fair value, a 37% upside to its current price.

Exploring Other Perspectives

Before this enrollment news, the most optimistic analysts were already assuming about US$63,400,000 of revenue and US$10,200,000 of earnings by 2028, which is far more upbeat than the baseline view, so you should expect that their confidence in EMPEROR’s progress and funding through mid 2028 might shift as new data arrive and consider how differently you might weigh those same uncertainties.

Explore 4 other fair value estimates on Stoke Therapeutics - why the stock might be worth less than half the current price!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Stoke Therapeutics research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Stoke Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Stoke Therapeutics' overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• Find 45 companies with promising cash flow potential yet trading below their fair value.
• Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• Uncover the next big thing with 20 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.